Overall, these results demonstrate that PD-L1 is commonly expressed in a variety of advanced solid tumors, with a prevalence of ≥50% in eight of the ten tumor types evaluated, and that PD-L1 expression is not associated with improvement in OS after either first-line or second-line SOC therapy. The gene discussed is CD274; the disease is neoplasm.